Embecta's Pivot: From Insulin Legacy to Pharma Services via Owen Mumford

Cost controls lift margins even as the U.S. insulin pen franchise erodes

EMBC · Earnings Call · 2026-08-07

Embecta's fiscal third quarter was a study in contrasts: a sharp sequential rebound in revenue and profit, layered on top of a still-deteriorating U.S. core business and a newly closed transformative acquisition. The company reaffirmed full-year revenue guidance of $1.015–$1.035 billion but raised adjusted operating margin guidance by 100 basis points at the midpoint and lifted adjusted EPS guidance by $0.20. The message: cost discipline, not top-line optimism, is carrying the year.

A Quarter of Two Halves

Total revenue fell 8.9% on a constant-currency basis to $272 million, but improved roughly $50 million sequentially as U.S. and international performance normalized and Owen Mumford contributed for the first time. In the U.S., revenue collapsed 24.6% year-over-year to $121 million, though it recovered $25 million sequentially. Devdatt Kurdikar stressed that the company is “tracking within the range of expectations that we laid out 90 days ago” — Devdatt Kurdikar, Chief Executive Officer · 2026-08-07, pointing to sequential stability in insulin pen prescriptions even as year-over-year declines in the retail channel widened. International revenue rose 11.5% reported (9.7% constant currency), with strength in Latin America and Asia offsetting continued softness in China.

Owen Mumford: The Engine of the Pivot

The strategic rationale for the Owen Mumford acquisition is now taking operational shape. Integration is proceeding, and the company has created a dedicated pharmaceutical services organization under a newly appointed President. The crown jewel is the Aidaptus auto-injector platform, which addresses a $2.4 billion total addressable market growing at double-digit rates.

We are not standing still, and the steps we are taking, strengthening our commercial execution in the U.S., integrating Owen Mumford and maintaining discipline in our cost structure and capital allocation are purposeful and aligned with our long-term strategic road map.
Devdatt Kurdikar, Chief Executive Officer · 2026-08-07

The acquisition expands Embecta well beyond its historical insulin injection devices business, adding point-of-care testing and self-injection devices.

In announcing Jeff Mann as head of pharma services, Devdatt Kurdikar noted: “Our conviction in the strategic rationale remains unchanged.” — Devdatt Kurdikar, Chief Executive Officer · 2026-08-07 That conviction is backed by a commercial pipeline that already includes secured long-term agreements for Aidaptus.

The U.S. Crosscurrent: GLP-1, Payer Mix, and the Road Back

While Owen Mumford provides the long-term growth story, the near-term battle remains in the U.S., where Embecta's core pen needle franchise is being squeezed from multiple sides. Total prescriptions for insulin pens continue to decline year-over-year, a trend management attributes partly to the accelerating affordability of GLP-1 therapies and shifts in the insured population. As Devdatt Kurdikar commented in May: “if we look at prescriptions for insulin pens, we have now begun to see a decline maybe more pronounced in the most recent quarter that we reported.” — Devdatt Kurdikar, Chief Executive Officer · 2026-05-05 That call noted that the company was already in discussions with over 30 potential generic GLP-1 entrants: “we are in discussions with 30 plus potential GLP-1 entrants.” — Devdatt Kurdikar, CEO · 2025-11-25 In the current quarter, those discussions have translated into tangible launches: Embecta pen needles are now co-packaged with generic GLP-1 drugs in Canada, Brazil, and most recently South Africa, following India.

The U.S. also offers a new incremental opportunity: “In the coming months, we also expect to launch a pen needle small pack format in the U.S. to support those patients using Zepbound, which was recently made available in a pen injector format.” — Devdatt Kurdikar, Chief Executive Officer · 2026-08-07 This ties directly to the auto injector and drug-delivery ecosystems, although management was careful not to quantify the contribution.

Margin Discipline and the Raised Bar

The bottom line this quarter is that cost optimization, not revenue, is driving the upside. Adjusted operating margin guidance was raised to 23.5%–24% from 22.25%–23.25%, and adjusted EPS guidance to $1.80–$1.90 from $1.55–$1.75. Jake Elguicze explained: “we are raising our adjusted operating margin guidance from a range of between 22.25% and 23.25% to a new range of between 23.5% and 24%.” — Jake Elguicze, Chief Financial Officer · 2026-08-07 This margin math matters because the top line is still shrinking. Embecta's gross margin fell to 57.6% in the latest quarter, down 5.7 percentage points year-over-year, reflecting lower U.S. revenue and one-time inventory and profit adjustments. The company expects these operating expense controls to generate further annualized benefits in 2027, providing a bridge to a more stable earnings profile.

With Owen Mumford integration on track, a newly restructured commercial organization under Nimish Muzumdar, and cost optimization efforts underway, Embecta is playing a long game. The immediate question is whether the U.S. franchise stabilizes before the new growth engines scale.